Science in Sport plc Stocks

£ 33.5Last Updated 16.06.2025

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

£ 103.04M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 33.5
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Science in Sport plc, together with its subsidiaries, develops, manufactures, and markets sports nutrition products for professional athletes, sports and fitness enthusiasts, and the active lifestyle community. The company offers energy bars, gels, powders, and shots; hydration products, such as gels, tablets, and powders; recovery products; supplements; and vitamins. It sells its products under the PhD Nutrition and Science in Sport brand names through retail distribution, including supermarkets and high street chains; specialist sports retailers; grocers; convenience and discount retailers; and international wholesalers, retailers, and distributors, as well as phd.com and scienceinsport.com digital platforms, third-party online sites in the United Kingdom, rest of Europe, the United States, and internationally. Science in Sport plc was founded in 1992 and is headquartered in London, the United Kingdom.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks